Paper Details

  1. Home
  2. Paper Details

A glycopyrronium bromide 1% cream for topical treatment of primary axillary hyperhidrosis: efficacy and safety results from a phase IIIa randomized controlled trial.

Author: AbelsC, Heimstaedt-MuskettS, JourdanC, KilicA, KnieU, MasurC, ReichH, SchrammK, SoeberdtM, SzeimiesR-M

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This phase IIIa study assessed the efficacy, safety, and tolerability of a 4-week topical treatment of glycopyrronium bromide (GPB) 1% cream in patients with primary axillary hyperhidrosis. The study found that GPB 1% cream significantly reduced sweat production, improved quality of life, and was well-tolerated. The study suggests that GPB 1% cream may provide an effective and safe new treatment option for patients with primary axillary hyperhidrosis.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Effective topical treatment options for patients with primary axillary hyperhidrosis (PAHH) are limited. A phase I trial showed promising results regarding the efficacy and safety of a topical cream containing glycopyrronium bromide (GPB). OBJECTIVES: To assess the efficacy, safety and ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451866/

データ提供：米国国立医学図書館（NLM）

Glycopyrronium Bromide: A Potential New Treatment for Axillary Hyperhidrosis

As a researcher with a keen interest in dermatological conditions, I'm always looking for innovative treatments that improve the lives of patients. This study explores the potential of glycopyrronium bromide (GPB) as a topical treatment for primary axillary hyperhidrosis (PAHH), a condition characterized by excessive sweating in the armpits.

The authors conduct a phase IIIa randomized controlled trial, meticulously comparing the efficacy and safety of a 1% GPB cream with a placebo in patients with PAHH. They carefully measure sweat production, assess the impact of the condition on patients' lives, and monitor for any adverse events.

The study reveals that GPB 1% cream significantly reduces sweat production and improves quality of life compared to placebo. It demonstrates that GPB is safe and well-tolerated, with most adverse events being mild and transient.

Glycopyrronium Bromide: A Potential New Treatment for Axillary Hyperhidrosis

This study suggests that GPB 1% cream could be a promising new treatment for PAHH. Its effectiveness in reducing sweat production and improving quality of life, coupled with its favorable safety profile, makes it a potentially valuable addition to the treatment arsenal for this challenging condition.

Effective and Safe Treatment for Axillary Hyperhidrosis

This study offers hope for individuals struggling with PAHH. GPB 1% cream emerges as a potentially effective and safe treatment option, providing relief from excessive sweating and improving quality of life.

Dr. Camel's Conclusion

This study highlights the potential of GPB 1% cream as a safe and effective treatment option for PAHH. The findings suggest that this medication could offer significant relief from excessive sweating and improve the quality of life for patients with this challenging condition.

Date :
  1. Date Completed 2021-09-20
  2. Date Revised 2021-09-29
Further Info :

Pubmed ID

33445205

DOI: Digital Object Identifier

PMC8451866

Related Literature

Article Analysis
・Effects of glycopyrronium topical
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.